Contribute Try STAT+ Today

Although it is widely known that drug and device makers fund most clinical trials, a new analysis finds these companies are not always transparent about the influence they exert on trial design and reporting. And the researchers suggest business concerns may too often trump patient interests.

On the plus side, the analysis found the vast majority of academics and their industry partners, including contract research organizations, contributed to trial design and reporting. And four of five academics had complete access to all of the data generated by the trials that were examined, according to the analysis, which was published in BMJ.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.